Commentary: The North West London Clinical Trials Alliance: efficiency and innovation in clinical trial delivery

被引:0
|
作者
Kierkegaard, Patrick [1 ,2 ]
Su, Bowen [1 ,2 ]
Wong, Richard [5 ]
Boffito, Marta [3 ,4 ]
Balendra, Suki [3 ]
机构
[1] Imperial Coll London, Canc Res UK Convergence Sci Ctr, London, England
[2] Inst Canc Res, London, England
[3] Imperial Coll Healthcare NHS Trust, London, England
[4] Chelsea & Westminster Hosp NHS Fdn Trust, London, England
[5] NIHR Res Delivery Network, London, England
关键词
Clinical trials; Clinical Trials Alliance; COVID-19; Vaccine trials; Digital tools; Participant recruitment; Efficiency; Inclusivity; Equity; Diversity; and Inclusion (EDI); Public health;
D O I
10.1186/s13063-024-08344-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The set-up, activation, and delivery of clinical trials is pivotal for the advancement of medical science, serving as the primary mechanism through which new therapeutic interventions are validated for clinical use. Despite their critical role, the execution of these trials is often encumbered by a multitude of challenges. The North West London Clinical Trials Alliance (The Alliance) was established to address these complexities. It aims to bridge the gap between emerging scientific research and its clinical application through strategic collaborations among healthcare and research entities, thereby enhancing the regional ecosystem for clinical trials. Main text This commentary aims to offer clarity on the fundamental insights that underlie The Alliance, providing a comprehensive understanding of its operational structure and the ecosystem it has fostered to optimise clinical trial delivery and revenue generation. The strategy employed by The Alliance centres on the cultivation of strategic partnerships across a broad spectrum of stakeholders. This approach addresses key operational challenges in clinical trial management, facilitating improvements in the development, setup, activation, and recruitment stages. Notably, The Alliance has reduced the average time to initiate trials to 19 days, compared to the standard 75 days typically observed for commercial setups in North West London. The effectiveness of The Alliance's framework was notably demonstrated during the COVID-19 pandemic, particularly with the expedited recruitment performance in the Janssen COVID-19 vaccine study conducted at Charing Cross Hospital. This instance highlighted the Alliance's capability to meet and exceed recruitment targets promptly while maintaining diversity within study cohorts. Additionally, The Alliance has effectively harnessed digital technology and infrastructure, enhancing its attractiveness to commercially funded studies and illustrating a sustainable model for clinical trial financing and execution. Conclusion The North West London Clinical Trials Alliance represents a strategic response to the conventional challenges faced in clinical trial management, emphasising the importance of cross-sectoral collaboration and resource optimisation. Its efforts, particularly highlighted by its response to the COVID-19 pandemic, provide a case study in enhancing trial delivery and efficiency with significant implications for both regional and global clinical trials research communities.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] A Commentary on Transdermal Drug Delivery Systems in Clinical Trials
    Watkinson, Adam C.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (09) : 3082 - 3088
  • [2] Independent clinical trials: A commentary
    Cocconi, G
    TUMORI, 2002, 88 (02) : 85 - 88
  • [3] The therapeutic alliance in randomized controlled clinical trials
    Kossoy, A
    Wilner, PJ
    FORSCHENDE KOMPLEMENTARMEDIZIN, 1998, 5 : 31 - 36
  • [4] Spotlight commentary: Innovations in clinical trials
    Hudej, Natasa
    Aumiler, Matea Radacic
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [5] On the efficiency of targeted clinical trials
    Maitournam, A
    Simon, R
    STATISTICS IN MEDICINE, 2005, 24 (03) : 329 - 339
  • [6] Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry
    Xu, Peng
    Xing, Xiangyu
    Yu, Keying
    Lv, Zhiguo
    Cui, Huijing
    Shi, Yuhang
    Chang, Tianying
    Zhang, Dongmei
    Zhang, Yibin
    Wang, Kai
    Lu, Jing
    Huang, Qingxia
    Li, Xiangyan
    Cui, Yingzi
    Shi, Li
    Wang, Tan
    Niu, Junqi
    Wang, Jian
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 1695 - 1701
  • [7] Immunotherapy: clinical trials - optimal trial and clinical outcomes
    Bousquet, Philippe Jean
    Demoly, Pascal
    Passalacqua, Giovanni
    Canonica, G. Walter
    Bousquet, Jean
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 7 (06) : 561 - 566
  • [8] Clinical trial participation among underserved communities: Insights from the Louisiana Community Engagement Alliance
    Craig, Leslie S.
    Sarpong, Daniel F.
    Peacock, Erin M.
    Theall, Katherine P.
    Williams, Lakeisha
    Al-Dahir, Sara
    Davis, Terry C.
    Arnold, Connie L.
    Williams, Allie
    Fields, Tynesia
    Wilson, Michelle
    Krousel-Wood, Marie
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2023, 366 (04) : 254 - 262
  • [9] Paediatric clinical trials need paediatric clinical trial budgets
    Koulizakos, Stavros
    Kjellen, Tina
    Mellgren, Karin
    Kindblom, Jenny M.
    ACTA PAEDIATRICA, 2023, : 1982 - 1985
  • [10] Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs
    van Eijk, Ruben P. A.
    Nikolakopoulos, Stavros
    Ferguson, Toby A.
    Liu, Dawei
    Eijkemans, Marinus J. C.
    van den Berg, Leonard H.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2018, 98 : 80 - 88